Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy.

Bland AE, Everett EN, Pastore LM, Andersen WA, Taylor PT Jr.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):629-36.

PMID:
17986246
2.

Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.

Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):621-8.

PMID:
17868339
3.

Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.

Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT Jr.

Am J Obstet Gynecol. 2006 Aug;195(2):568-74; discussion 574-6.

PMID:
16890558
4.

Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.

Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS.

Cancer. 1998 May 1;82(9):1731-7.

PMID:
9576296
5.

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Dec;103(3):1083-90.

PMID:
16890277
6.

Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer.

Deo SV, Goyal H, Shukla NK, Raina V, Kumar L, Srinivas G.

Indian J Cancer. 2006 Jul-Sep;43(3):117-21.

7.

Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.

Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, Disilvestro P, Gordinier ME, Moore R, Tejada-Berges T, Pires L, Legare R, Granai CO.

Gynecol Oncol. 2006 Feb;100(2):417-21.

PMID:
16336992
8.

Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.

Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM.

Gynecol Oncol. 2000 Aug;78(2):171-5.

PMID:
10926798
9.

Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.

Bilici A, Salepci T, Dane F, Gumus M, Ustaalioglu BB, Seker M, Salman T, Turan C, Unal O, Yaylaci M.

Arch Gynecol Obstet. 2010 Oct;282(4):417-25. doi: 10.1007/s00404-009-1330-7.

PMID:
20035339
10.

Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer.

Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, Bridges JE.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):42-50.

PMID:
14764028
11.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group..

J Clin Oncol. 2008 Jan 1;26(1):83-9.

PMID:
18025437
12.

Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY.

Gynecol Oncol. 2011 Jan;120(1):18-22. doi: 10.1016/j.ygyno.2010.09.024.

PMID:
21035174
13.

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE.

Gynecol Oncol. 2007 Apr;105(1):211-7.

PMID:
17239941
14.
15.

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

Kang S, Nam BH.

Ann Surg Oncol. 2009 Aug;16(8):2315-20. doi: 10.1245/s10434-009-0558-6.

PMID:
19517192
16.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014.

PMID:
21917306
17.

Intestinal surgery in treatment of advanced ovarian cancer--review of our experience.

Stefanović A, Jeremić K, Kadija S, Milincić N, Mircić A, Petković S, Zizić V.

Eur J Gynaecol Oncol. 2011;32(4):419-22.

PMID:
21941966
18.

The place of bowel resection in initial debulking surgery for advanced ovarian cancer.

Miller J, Proietto A.

Aust N Z J Obstet Gynaecol. 2002 Nov;42(5):535-7.

PMID:
12495103
19.

Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India.

Basu P, De P, Mandal S, Ray K, Biswas J.

Indian J Cancer. 2009 Jan-Mar;46(1):28-33.

20.

The role of bowel surgery with cytoreduction for epithelial ovarian cancer.

Cai HB, Zhou YF, Chen HZ, Hou HY.

Clin Oncol (R Coll Radiol). 2007 Dec;19(10):757-62.

PMID:
17889517
Items per page

Supplemental Content

Support Center